Karuna Therapeutics (NASDAQ:KRTX) Receives Buy Rating from H

HC Wainwright reissued their buy rating on shares of Karuna Therapeutics (NASDAQ:KRTX – Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has a $300.00 target price on the stock. Several other research firms also recently weighed in on KRTX. Cantor Fitzgerald reiterated a neutral rating and […]

Related Keywords

United States , America , Jeffreym Jonas , Troya Ignelzi , , Financial Services Group Inc , Karuna Therapeutics Company Profile , Lazard Asset Management , Morgan Stanley , Exchange Traded Concepts , Almanack Investment Partners , Cantor Fitzgerald , First Horizon Advisors Inc , Karuna Therapeutics Inc , Securities Exchange Commission , Wells Fargo Company , Karuna Therapeutics , Free Report , Moderate Buy , Therapeutics Stock Down , Get Free Report , Director Jeffrey , Exchange Commission , Horizon Advisors , Services Group , Asset Management , Investment Partners , Karuna Therapeutics Daily , Nasdaq Krtx , Krtx , Medical , Reiterated Rating , Hc Wainwright ,